Article

Genomic profiling of young-onset g<i>BRCA1/2</i> breast cancer reveals distinct genomic landscapes and therapeutic implications for PARP and CDK4/6 inhibitor selection

2025-09-21

Abstract excerpt

<h4>Purpose</h4> g BRCA1/2 pathogenic variant (PV) carriers have elevated young-onset breast cancer risk. Understanding the distinct genomic landscapes of g BRCA1- and g BRCA2 -associated breast cancer, including presence of PARP and CDK4/6 inhibitor (PARPi; CDK4/6i) response-associated alterations, may inform treatment selection for these patients. <h4>Patients and methods</h4> We evaluated 136 treatment-naïve...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 137b5674-257e-5acd-a5a2-1b82929ca84a
DOI: 10.1101/2025.09.19.25336150

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Genomic profiling of young-onset g<i>BRCA1/2</i> breast cancer reveals distinct genomic landscapes and therapeutic implications for PARP and CDK4/6 inhibitor selectionDOI 10.1101/2025.09.19.25336150Read

Comparative analysis of distinct genomic landscapes in young-onset gBRCA1/2 breast cancer.Semantic proximity Read

Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancerSemantic proximity Read

Homologous Recombination Deficiency Landscape of Breast Cancers and Real-World Effectiveness of Poly ADP-Ribose Polymerase Inhibitors in Patients With Somatic BRCA1/2, Germline PALB2, or Homologous Recombination Deficiency SignatureSemantic proximity Read

Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.Semantic proximity Read

Validation of Genomic and Transcriptomic Models of Homologous Recombination Deficiency in a Real-World Pan-Cancer CohortSemantic proximity Read

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.Semantic proximity Read

Hereditary Breast and Ovarian Cancer Syndrome: Moving Beyond BRCA1 and BRCA2Semantic proximity Read

The utility of homologous recombination deficiency biomarkers across cancer typesSemantic proximity Read

Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.Semantic proximity Read

Genetic Basis of Breast and Ovarian Cancer: Approaches and Lessons Learnt from Three Decades of Inherited Predisposition TestingSemantic proximity Read

Aneuploidy and deregulated DNA damage response define haploinsufficiency in breast tissues of <i>BRCA2</i> mutation carriersSemantic proximity Read

Whole Genome Analysis Identifies Homologous Recombination Deficiency in Cancers with BRCA1/2 Wild-Type and BRCA1/2 Structural VariantsSemantic proximity Read